GBIM:OTCMKTS
GlobeImmune Inc
0,00010 US$
0,00%
(0,00) 1D
29 sht, 3:48:52 m.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për GBIM...
Kapitalizimi i tregut
580,00
Vëllimi mesatar
1,74 mijë
Vëllimi
0,00
Maksimumi 52-javor
0,04 US$
Minimumi 52-javor
0,00 US$
Aksionet në qarkullim
5,75 mln
Numri i punonjësve
22
Kapitalizimi i tregut
580,00
Vëllimi mesatar
1,74 mijë
Vëllimi
0,00
Maksimumi 52-javor
0,04 US$
Minimumi 52-javor
0,00 US$
Aksionet në qarkullim
5,75 mln
Numri i punonjësve
22
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
GlobeNewswire
·
30 minuta më parë
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seeking Alpha
·
36 minuta më parë
3 things to look out for on Monday
Stock Titan
·
34 minuta më parë
After failing to show $2.5M in equity, Callan JMB (NASDAQ: CJMB) appeals Nasdaq’s decision.
Yahoo Finance
·
15 minuta më parë
GreenPower Announces Receipt of Letter from NASDAQ
Profili
GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases. As of August 2014, the company had no marketed products. GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.
The company has partnerships with Celgene and the National Cancer Institute for the development of cancer vaccines. Their collaboration with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B was terminated in November 2016 after the product they were developing failed a clinical trial the year before.
With respect to financing in the absence of revenue, the company raised US$17,500,000 through a Series E Preferred Stock offering in January 2010.
As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers. Wikipedia
Rreth GlobeImmune Inc
Drejtori ekzekutiv-
Punonjësit22
Themeluar më1 jan 1995
SeliaLouisville, Colorado, Shtetet e Bashkuara të Amerikës
Sektori-
Uebsajtiglobeimmune.com